Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vera Golder

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Arthritis Research & Therapy|June 22, 2022
Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional studySidha Sreedharan, Ning Li, Geoff Littlejohn, et al.
Lupus Science & Medicine|February 28, 2023
Clinical associations of cognitive dysfunction in systemic lupus erythematosusSudha Raghunath, Yifat Glikmann-Johnston, Vera Golder, et al.
Arthritis Care & Research|July 9, 2019
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus ErythematosusAi Li Yeo, Rachel Koelmeyer, Rangi Kandane-Rathnayake, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 14, 2026
Modeling SLE Treatment Cost-Effectiveness Based on a Novel LLDAS Treat-to-Target ApproachMaria Farris, Jenna Christensen, Vera Golder, et al.
Seminars in Arthritis and Rheumatism|September 26, 2022
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysisTina Ko, Rachel Koelmeyer, Ning Li, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
Seminars in Arthritis and Rheumatism|February 21, 2017
Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity studyVera Golder, Molla Huq, Kate Franklyn, et al.
The Lancet. Rheumatology|January 23, 2024
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort studyDiane Apostolopoulos, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
The Lancet. Rheumatology|January 17, 2024
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
The Lancet. Rheumatology|January 17, 2024
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Arthritis Research & Therapy|June 22, 2022
Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional studySidha Sreedharan, Ning Li, Geoff Littlejohn, et al.
Lupus Science & Medicine|February 28, 2023
Clinical associations of cognitive dysfunction in systemic lupus erythematosusSudha Raghunath, Yifat Glikmann-Johnston, Vera Golder, et al.
Arthritis Care & Research|July 9, 2019
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus ErythematosusAi Li Yeo, Rachel Koelmeyer, Rangi Kandane-Rathnayake, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 14, 2026
Modeling SLE Treatment Cost-Effectiveness Based on a Novel LLDAS Treat-to-Target ApproachMaria Farris, Jenna Christensen, Vera Golder, et al.
Seminars in Arthritis and Rheumatism|September 26, 2022
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysisTina Ko, Rachel Koelmeyer, Ning Li, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
Seminars in Arthritis and Rheumatism|February 21, 2017
Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity studyVera Golder, Molla Huq, Kate Franklyn, et al.
The Lancet. Rheumatology|January 23, 2024
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort studyDiane Apostolopoulos, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
The Lancet. Rheumatology|January 17, 2024
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
The Lancet. Rheumatology|January 17, 2024
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
Pageof 5